OCULAR THERAPEUTIX, INC (OCUL) Form 8-K — Jun 12, 2026

$OCULForm 8-KItems 5.02, 5.07, 9.01Filed Jun 12, 2026, 4:23 PM ET0001104659-26-073496Original filing

Ocular Therapeutix appointed Jason Robins as permanent Chief Financial Officer, transitioning him from his interim role held since January 2026. His compensation package includes a base salary of $535,100, a target bonus of 45%, and equity awards consisting of 14,024 stock options and 15,441 restricted stock units. At its 2026 Annual Meeting, stockholders approved Amendment No. 5 to the 2021 Stock Incentive Plan, increasing the number of shares available for issuance by 10,000,000.

Key figures

Cfo base salary: $535,100
Cfo bonus target: 45%
Cfo rsus granted: 15,441 shares
Cfo options granted: 14,024 shares
Stock plan increase: 10,000,000 shares

Price after filing

1 day: 0.0%7 days: +8.4%30 days: +21.1%

Close on the filing date to close N calendar days later (from $8.70). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.